Literature DB >> 19747731

Multicentric Castleman disease complicated by tumor lysis syndrome after systemic chemotherapy.

Ji Hyun Lee, Kyung A Kwon, Suee Lee, Sung Yong Oh, Hyuk-Chan Kwon, Jin Yeong Han, Sook Hee Hong, Sung-Hyun Kim.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19747731     DOI： 10.1016/j.leukres.2009.08.025

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  5 in total

1.  Clinicopathological Profile of Castleman's Disease in Indian Population: Experience From a Tertiary Care Center.

Authors:  Ashok Singh; Suvendu Purkait; Saumyaranjan Mallick; Prashant Ramteke; Chandan Krushna Das; Ajay Gogia; Maher Chand Sharma; Lalit Kumar
Journal:  Indian J Hematol Blood Transfus       Date:  2019-09-25       Impact factor: 0.900

Review 2.  Castleman's disease: from basic mechanisms to molecular therapeutics.

Authors:  Hazem E El-Osta; Razelle Kurzrock
Journal:  Oncologist       Date:  2011-03-25

3.  Clinical characteristics and prognosis of patients with Castleman disease in a Chinese hospital: paraneoplastic pemphigus is an independent risk factor.

Authors:  Yibo Hua; Chao Liang; Jie Yang; Luyang Wang; Aimin Xu; Lei Xi; Shangqian Wang; Zengjun Wang
Journal:  Am J Transl Res       Date:  2022-02-15       Impact factor: 4.060

Review 4.  Tumor Lysis-like Syndrome in Eosinophilic Disease of the Lung: A Case Report and Review of the Literature.

Authors:  Seiya Urae; Kayori Tsuruoka; Sayaka Kuroya; Yugo Shibagaki
Journal:  Intern Med       Date:  2016-10-15       Impact factor: 1.271

5.  Clinical characteristics and outcomes of Castleman disease: A multicenter study of 185 Chinese patients.

Authors:  Xuanye Zhang; Huilan Rao; Xiaolu Xu; Zhihua Li; Bing Liao; Hongmei Wu; Mei Li; Xiuzhen Tong; Juan Li; Qingqing Cai
Journal:  Cancer Sci       Date:  2017-12-28       Impact factor: 6.716
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.